Clinical Trial Update: A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intermittent oral dosing of ASP1517 in patients with chronic kidney disease undergoing peritoneal dialysis and anemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• ASP1517

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia | Phase 3 | Status: COMPLETED